Unknown

Dataset Information

0

Myelodysplastic syndromes: diagnosis, prognosis, and treatment.


ABSTRACT: BACKGROUND: Myelodysplastic syndromes (MDS) are malignant stem-cell diseases that are usually diagnosed in elderly patients who present with anemia or, less commonly, bi- or pancytopenia. Their incidence in persons over age 80 is above 50 new cases per 100,000 persons per year. Their clinical course is highly variable. About one-quarter of all patients with MDS develop acute leukemia. The median survival time from the moment of diagnosis is about 30 months. METHOD: We selectively searched the PubMed database for pertinent articles and guidelines from the years 2000-2013. We used the search term "myelodysplastic syndromes." RESULTS: MDS are diagnosed by cytology, with consideration of the degree of dysplasia and the percentage of blast cells in the blood and bone marrow, and on a cytogenetic basis, as recommended in the WHO classification. In particular, chromosomal analysis is necessary for prognostication. The Revised International Prognosis Scoring System (IPSS-R) enables more accurate prediction of the course of disease by dividing patients into a number of low- and high-risk groups. The median survival time ranges from a few months to many years. The approved treatments, aside from transfusion therapy, include iron depletion therapy for low-risk patients, lenalidomide for low-risk patients with a deletion on the long arm of chromosome 5, and 5-azacytidine for high-risk patients. High-risk patients up to age 70 who have no major accompanying illnesses should be offered allogenic stem-cell transplantation with curative intent. The cure rates range from 30% to 50%. Mucositis, hemorrhages, infections, and graft-versus-host diseases are the most common complications of this form of treatment. CONCLUSION: Myelodysplastic syndromes are treated on an individualized, risk-adapted basis after precise diagnostic evaluation and after assessment of the prognosis. More studies are needed so that stage-adapted treatment can be improved still further.

SUBMITTER: Germing U 

PROVIDER: S-EPMC3855821 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Myelodysplastic syndromes: diagnosis, prognosis, and treatment.

Germing Ulrich U   Kobbe Guido G   Haas Rainer R   Gattermann Norbert N  

Deutsches Arzteblatt international 20131101 46


<h4>Background</h4>Myelodysplastic syndromes (MDS) are malignant stem-cell diseases that are usually diagnosed in elderly patients who present with anemia or, less commonly, bi- or pancytopenia. Their incidence in persons over age 80 is above 50 new cases per 100,000 persons per year. Their clinical course is highly variable. About one-quarter of all patients with MDS develop acute leukemia. The median survival time from the moment of diagnosis is about 30 months.<h4>Method</h4>We selectively se  ...[more]

Similar Datasets

| S-EPMC11327013 | biostudies-literature
| S-EPMC6347085 | biostudies-literature
| S-EPMC5967332 | biostudies-literature
| S-EPMC6142510 | biostudies-literature
| S-EPMC3811170 | biostudies-literature
| S-EPMC3716523 | biostudies-literature
| S-EPMC4340482 | biostudies-literature
| S-EPMC7783761 | biostudies-literature
| S-EPMC9600488 | biostudies-literature
| S-EPMC5902151 | biostudies-literature